Login or sign up
For business

Egenesis

4.1ยท 12 reviews
Average ratingGreat
4.1/ 5

Based on 12 reviews

533%
442%
325%
20%
10%
Ask AI

What reviewers say about Egenesis

Based on 12 reviews, listing data and website checks ยท updated 7 days ago

Customers describe Egenesis as a reliable, professional, and efficient partner that delivers quality work within timelines and maintains high standards of service and attention to detail.
What is Egenesis?

Egenesis is a biotechnology company developing human-compatible organs for transplantation, as reported by Biospace in 2026. The company is led by President and CEO Mike Curtis, Ph.D., and CFO Glenn S. Vraniak, who participate in investor conferences like the Jefferies Global Healthcare Conference. They are registered in the US and operate under the name eGenesis, Inc.

Who is the current leadership team?

The company recently appointed Daniel Leblanc as Chief Manufacturing and Supply Officer, bringing over 25 years of experience in manufacturing and technical operations to support clinical development and commercial readiness. This leadership change was announced in October 2026 to strengthen their manufacturing capabilities. The appointment highlights their focus on scaling up production for their organ development pipeline.

What is the core mission of the company?

According to Biospace, eGenesis is a biopharmaceutical company focused on engineering human-compatible organs for transplantation. They aim to solve organ shortage issues through advanced biotechnology. Their work involves developing organs that are compatible with human recipients, marking a significant step in medical science.

Where is the company based?

The company is located in Cambridge, Massachusetts, as indicated by the press releases from Biospace. This location places them in a major biotech hub, facilitating access to research facilities and talent. Their registered address is not explicitly listed in the provided news, but their operational base is confirmed to be in Cambridge.

What specific technology does the company develop?

eGenesis is actively seeking to develop human-compatible organs for transplantation, a critical need in modern medicine. Their technology focuses on creating organs that can be safely transplanted into patients without rejection. This approach aims to revolutionize organ availability and save lives.

How is the company preparing for commercial launch?

The company is preparing for commercial readiness by appointing experienced executives like Daniel Leblanc to oversee manufacturing and supply chains. This strategic move ensures that once their organs are developed, they can be produced and distributed efficiently. Their goal is to transition from research to large-scale clinical application.

How does the company communicate with investors?

As of November 2026, eGenesis is actively participating in investor conferences such as the Jefferies Global Healthcare Conference. These events allow them to present their progress to potential investors and partners. Their CEO and CFO are directly involved in these communications to maintain transparency and interest.

Who is the target audience for their products?

eGenesis is a biotech firm that does not yet have a publicly listed product for sale, but they are developing human-compatible organs. Their services are primarily research and development focused on organ transplantation. They target patients suffering from organ failure and shortage.

What are the potential benefits of their technology?

The company's approach involves engineering organs that are compatible with human recipients, reducing the need for immunosuppressive drugs. This method could significantly improve patient outcomes and reduce long-term healthcare costs. Their technology is designed to be a breakthrough in transplant medicine.

What expertise does the company possess?

The company's expertise lies in biotechnology and organ engineering, with a focus on transplantation. They are supported by experienced leadership in manufacturing and supply chain management. Their team includes scientists and engineers dedicated to solving the organ shortage crisis.

How long has the company been operating?

eGenesis is a US-based biotech company that has been active in the healthcare sector as of 2026. They are not a new startup but are building on existing research to create viable organ solutions. Their history is tied to ongoing advancements in biotechnology and transplantation medicine.

How does eGenesis compare with other biotech companies?

Biospace reported that eGenesis is developing human-compatible organs for transplantation, a field that is highly competitive. They are distinguishing themselves by focusing on manufacturing readiness and commercial scalability. Their approach aligns with the needs of hospitals and transplant centers looking for reliable organ sources.

How can I contact Egenesis?

You can reach Egenesis by phone at 4123671000.

What is the official website of Egenesis?

The official website of Egenesis is atitd.com.

Is Egenesis on social media?

Egenesis has official profiles on Linkedin.

AI-generated from reviews on this page. Verify anything important with the company directly.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website โ€” a simple way to convert your visitors into customers.

Get the widget for your site →

About Egenesis

Website
atitd.com
Address
105 Braunlich Dr
Categories
Computer games